Novartis DM1 Harbor Phase III misses primary endpoint; guidance held
Novartis’ Harbor Phase III study in DM1 did not meet its primary endpoint. Del-Desiran showed evidence of clinical activity in secondary endpoints, and the company maintained 5-6% five-year sales CAGR guidance for 2025-2030.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.